Home

Introduction

PalindromX Limited (PdX) specialises in developing state-of-the-art in vitro diagnostic (IVD) technologies. It is most active in the fields of super-sensitive, multiplexed immunoassay technology, DNA-based vaccination techniques and bone resorption testing services. PdX has generated an intellectual property portfolio in the first two areas that is expected to proceed to grant, providing a potentially lucrative future royalty stream.

Bone Resorption Services

PdX offers a custom in vitro bone resorption testing service to the pharmaceutical, biotechnology and research communities. PdX scientists and technical staff have many years experience in developing, undertaking and modifying in vitro resorption assays and its clients include multi-national companies. Standard assays are based on a bone slice/dentine disc assay in which osteoclasts excavate authentic resorption lacunae on calcified substrates. This service routinely uses human osteoclasts derived from peripheral blood, but assays using osteoclasts from many other species can be arranged.

DNA Vaccination

PdX has developed proprietary approaches to DNA vaccination to produce highly specific antibodies. The use of DNA vaccination has been recognised as a major tool in the development of specific reagent antibodies for both therapeutic and diagnostic use. However, the use of this approach has been restricted due to limited success in the sustainable production of specific antibodies. The patent-pending approach developed by PdX overcomes the problems encountered to date and provides a means to raise antibodies to the naturally expressed protein.

Super-Sensitive Immunoassay

PdX key focus area is in the development of next generation immunoassays. The combination of generic immunoassay techniques with the enhanced sensitivity of PCR has previously encountered difficulties such as cross-contamination of DNA into the immunoassay and high levels of non-specific binding and background noise that limit the application of such techniques in routine clinical practice. PdX patent-pending technique removes these obstacles and has enabled the company to demonstrate improvements in limits of detection of several thousand-fold (in buffer) to several hundred-fold (in serum) even in early prototype systems.

Multiplexed Immunoassay

PdX combines its super-sensitive immunoassay with simultaneous multi-analyte determination, enabling the discrimination of multiple different antibody-protein-antibody complexes within a single patient sample, using a technique termed Melt-Curve Analysis (MCA). This technique uses the characteristic thermal dissociation of several structurally different probes - in the same assay mixture - from their targets, as an effective detection technique.